Mariana Oncology, a Watertown MA-based fully integrated, next-generation radiopharmaceuticals company, raised $175m in Series B financing.
The round was co-led by Forbion (the first investment by its Forbion Ventures Fund VI,) and Deep Track Capital, with participation from founding investors Atlas Venture, Access Biotechnology and RA Capital Management, and new investors Nextech Invest, Surveyor Capital (a Citadel company) and Eli Lilly and Company. In conjunction with the fundraise, Forbion Managing Partner Geert-Jan Mulder, MD, will join the Board of Directors, alongside Rebecca Luse from Deep Track Capital, that co-led the funding round.
The company will use the proceeds to support the development of its portfolio of precision next generation radiopharmaceuticals, including its lead candidate MC-339, which targets small cell lung cancer.
Led by Simon Read, Ph.D., Founder and Chief Executive Officer, Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company focused on a new class of targeted peptide-based radiopharmaceuticals. The company’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets to deliver alpha or beta-emitting radionuclide payloads.
FinSMEs
07/09/2023